Why Myriad Genetics, Inc. Shares Soared

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Myriad Genetics  (NASDAQ: MYGN  ) are trading 11% higher today after the company delivered a one-two punch of good news to the markets. The company not only posted strong earnings and updated its full-year guidance to levels above Wall Street's consensus; it also acquired a rival diagnostics company.

So what: Myriad's fiscal second quarter showed excellent growth -- the company's revenue soared 37% higher year over year to reach $204.1 million, and earnings were $0.66 per share. Both numbers were well above what Wall Street expected as the consensus was for $175.1 million in revenue and $0.46 in EPS. Myriad now anticipates full-year revenue in the $740 million to $750 million range and full-year EPS in the $2.09 to $2.12 range. Wall Street was looking for $703.2 million on the top line and $1.96 on the bottom line, so Myriad is looking quite good for the two quarters remaining in its 2014 fiscal year.

Myriad didn't think stomping all over Wall Street's expectations was enough for one day, though. The company acquired privately held Crescendo Bioscience, an autoimmune diagnostics company, for $270 million, $25 million of which will repay Crescendo's outstanding loans. Crescendo's focus on rheumatoid arthritis was specifically noted as a major reason for the acquisition, as was its strength in protein-based diagnostics.

Now what: Myriad shares have been bouncing around between $20 and $30 for years, but revenue and earnings have both shown strong upward momentum in the past few years. At a P/E of just 14.4, Myriad is undeniably inexpensive for a sector that should experience strong growth in the coming years, and its acquisition should help bolster the bottom line over the long run as well. This pop seems to be the real deal, and if you were on the fence about Myriad before, you might want to take a closer look today.

Want more news and updates? Add Myriad Genetics to your Watchlist now.

Looking for other long-term stock superstars?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2825110, ~/Articles/ArticleHandler.aspx, 9/1/2015 10:38:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Alex Planes

Alex Planes specializes in the deep analysis of tech, energy, and retail companies, with a particular focus on the ways new or proposed technologies can (and will) shape the future. He is also a dedicated student of financial and business history, often drawing on major events from the past to help readers better understand what's happening today and what might happen tomorrow.

Connect with Alex on LinkedIn or Twitter for more news and insight:

View Alex Planes's profile on LinkedIn

Today's Market

updated 1 hour ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 3:59 PM
MYGN $36.65 Down -0.91 -2.42%
Myriad Genetics CAPS Rating: ***